Turning Fluids into Data for Precision Oncology: A Multidisciplinary Tumor Board Approach to Malignant Pleural Effusions
Authors:
- Domenico DamianiDDDomenico Damiani
- Ilaria GirolamiIGIlaria Girolami
- Esther HanspeterEHEsther Hanspeter
- Christine MianCMChristine Mian
- Christine SchwienbacherCSChristine Schwienbacher
- Johanna KöhlJKJohanna Köhl
- Stefania KinspergherSKStefania Kinspergher
- Giovanni ZambelloGZGiovanni Zambello
- Francesco ZaracaFZFrancesco Zaraca
- Giovanni NegriGNGiovanni Negri
- Patrizia PernterPPPatrizia Pernter
- Mohsen FarsadMFMohsen Farsad
Open Access
- 16 March 2026
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 14 (3) , 673
Abstract
Background: Malignant pleural effusion (MPE) represents a frequent and clinically challenging manifestation of advanced malignancy, particularly in metastatic non-small cell lung cancer (NSCLC). Its management requires integration of diagnostic imaging, symptom-directed therapeutic strategies, and, increasingly, molecular profiling technologies. Recent advancements in this field based on liquid medium (so-called liquid biopsy) have achieved a significant increase in sensitivity, enhancing our ability to investigate biofluids and suggesting their potential integration into standard diagnostic practices, far beyond the canonical plasma biopsies. Fluid obtained from MPE after cytological sample centrifugation is rich in cell-free DNA and less susceptible to nucleic acid degradation during processing, improving overall diagnostic accuracy. Methods: This narrative review summarizes current evidence on the clinical management of malignant pleural effusions in patients with metastatic NSCLC, integrating imaging, procedural management, and molecular profiling from a multidisciplinary tumor board perspective. The primary objective was to synthesize contemporary knowledge with particular attention to the feasibility, reliability, and reproducibility of pleural fluid-based molecular testing. Results: MPE poses diagnostic and therapeutic challenges for all members of the multidisciplinary tumor board, traditionally associated with an adverse prognosis. However, recent advances in cytopathology, histopathology, and liquid-based techniques demonstrate that MPE could be an important source of prognostic or predictive information. At the same time, optimal patient management requires careful integration of imaging findings and procedural strategies (such as pleurodesis or indwelling pleural catheters) with individualized systemic therapy selection. Cell-free DNA in pleural effusions is a promising field of exploration and study, potentially suitable for future guideline implementation, after validation in adequately powered studies, contributing to improving patient management, particularly useful in fragile subsets. Conclusions: The management of MPE in advanced NSCLC is evolving toward a multidisciplinary, precision-oriented model that integrates clinical evaluation, imaging, procedural interventions, and molecular testing. Liquid biopsy technology has gained enough analytical robustness and clinical feasibility to be a useful tool in routine analysis. Biofluid-based molecular testing may have outstanding potential, contributing to improving patient management, avoiding repetitive procedures, and optimizing the overall efficiency and cost-effectiveness of diagnostic practices. Moreover, collaborative projects among different specialties help in consolidating trust in the tumor board decision-making process.Keywords
This publication has 62 references indexed in Scilit:
- Extraction, Purification, and Next-Generation Sequencing (NGS) Analysis of DNA and RNA from Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue2024
- Preservation of cfRNA in cytological supernatants for cfDNA & cfRNA double detection in non‐small cell lung cancer patientsCancer Medicine, 2024
- Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With CancerJAMA Oncology, 2022
- Evidence‐based diagnostic performance of novel biomarkers for the diagnosis of malignant mesothelioma in effusion cytologyCancer Cytopathology, 2021
- Performance of a 50‐gene next generation sequencing panel with post‐centrifuge supernatant cytology fluid in non‐small‐cell lung cancerDiagnostic Cytopathology, 2021
- Targeted deep sequencing of cell‐free DNA in serous body cavity fluids with malignant, suspicious, and benign cytologyCancer Cytopathology, 2019
- Development and validation of the PET-CT score for diagnosis of malignant pleural effusionEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural EffusionJAMA, 2017
- Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utilityGenes, Chromosomes and Cancer, 2017
- Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural EffusionJAMA, 2012